Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AcelRx Pharmaceuticals has received $5.6m grant from the US Army Medical Research and Material Command (USAMRMC) to develop ARX-04 as a treatment for moderate-to-severe acute pain drug.
Subscribe to our email newsletter
ARX-04 is a proprietary non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.
As per the terms of the grant, the USAMRMC is expected to support the development, manufacturing and clinical costs for preparing and completing the intended Phase 2 dose-finding trial to AcelRx.
The grant will also support the company to enter into Phase 3 development.
AcelRx president and CEO Richard King said ARX-04, a single dose, higher strength iteration of their ARX-01 product, represents a promising new application of their proprietary NanoTab technology for sublingual delivery of sufentanil, and has the potential to safely provide rapid onset of analgesia for patients in acute pain, both on the battlefield and in civilian settings of trauma or injury.
"USAMRMC has provided AcelRx with a grant to support development of ARX-04 through completion of a Phase 2 study, which we will begin in the second half of 2011," King said.